Author: Sangeun Jeon; Meehyun Ko; Jihye Lee; Inhee Choi; Soo Young Byun; Soonju Park; David Shum; Seungtaek Kim
Title: Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Document date: 2020_3_20
ID: 5f95gve3_4
Snippet: Drug repositioning could be an effective strategy to respond immediately to emerging infectious diseases since the new drug development usually takes more than 10 years 4 . FDA-approved drugs provide safe alternatives only in the case where at least modest antiviral activity can be achieved. Accordingly, several drugs are being tested in numerous clinical trials 5 including remdesivir, lopinavir, and chloroquine 6 ......
Document: Drug repositioning could be an effective strategy to respond immediately to emerging infectious diseases since the new drug development usually takes more than 10 years 4 . FDA-approved drugs provide safe alternatives only in the case where at least modest antiviral activity can be achieved. Accordingly, several drugs are being tested in numerous clinical trials 5 including remdesivir, lopinavir, and chloroquine 6 .
Search related documents:
Co phrase search for related documents- antiviral activity and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral activity and Drug repositioning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- antiviral activity and effective strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- antiviral activity and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- antiviral activity and modest antiviral activity: 1, 2, 3, 4, 5
- antiviral activity and new drug development: 1, 2, 3, 4, 5, 6
- antiviral activity and safe alternative: 1, 2
- antiviral activity and safe alternative provide: 1
- clinical trial and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical trial and Drug repositioning: 1, 2, 3, 4, 5, 6, 7, 8
- clinical trial and effective strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- clinical trial and FDA approve: 1
- clinical trial and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- clinical trial and new drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- clinical trial and safe alternative: 1, 2, 3, 4, 5, 6, 7, 8, 9
- drug development and effective strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- drug development and immediately respond: 1
- drug development and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- drug development and new drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Co phrase search for related documents, hyperlinks ordered by date